How does COSM's Q4 2023 forecast compare to past quarters?

Cosmos Health Inc. (COSM) does not appear to have specific revenue forecasts for Q4 2023 recorded in the databases. However, the company's financial performance and strategic initiatives can be analyzed based on the available data. 1. **Comparing Forecasted Revenue**: There are no recorded forecasts for Q4 2023, Q3 2023, Q2 2023, or Q1 2023. This absence makes it challenging to assess trends or changes in forecasted revenue across quarters. 2. **Analyzing Recent Developments**: - **Strategic Inflection Point**: Cosmos Health has reached a major strategic inflection point, with operations and revenue ramp-up underway, poised to significantly accelerate in 2024 and beyond. - **Acquisitions Impact**: The company's acquisitions, including Cana Laboratories, the distribution network owned by Bikas GP, and ZipDoctor, are projected to contribute almost $4 million in incremental group annual revenue in FY 2023 and significantly more by FY 2024. - **Research and Development**: Notable progress in R&D is being made, with products advancing through various stages, including clinical trials. The spinoff of the R&D division into a standalone biotech company is a strategic move to maximize value from these developments. - **Financial Position**: The company maintains a solid balance sheet with negligible debt and a strong, diversified asset base. The book value exceeds $4 per share, which is more than three times the current share price. - **Stock Performance and Buybacks**: The stock has seen a 14.25% rise after the CEO announced an intention to buy up to $3 million in shares, indicating confidence in the company's future. A stock buyback program has been announced, authorizing the purchase of up to $3 million in common stock. 3. **Growth Expectations**: - **Inaugural 2026 Guidance**: Cosmos Health has introduced inaugural guidance for 2026, expecting over $180 million in gross annual revenue and EBITDA in excess of $20 million. This guidance reflects confidence in substantial growth and profitability. - **Recent Performance**: In Q2 2023, the company reported revenues of $12.36 million, with an adjusted EPS of $0.01, improved from a $(0.35) loss in the prior year. This indicates a positive trend in profitability. In conclusion, while specific quarter-over-quarter comparisons for COSM's forecasted revenue in 2023 are not available, the company's strategic initiatives, acquisitions, and growth expectations suggest a positive outlook for future revenue growth. The introduction of 2026 guidance and recent financial improvements support the notion of a company on an upward trajectory.